ArticleAnimal models and experimental medicine2026
Identification of senescence-related genes in Parkinson's disease reveals candidate therapeutic targets and pathological processes.
Article in Animal models and experimental medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Identification of senescence-related genes in Parkinson's disease reveals candidate therapeutic targets and pathological processes.Animal models and experimental medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundParkinson's disease (PD), a progressive neurodegenerative disease, is closely linked to the aging process; however, its precise molecular mechanisms remain unclear. This work aimed at clarifying the function of senescence-related genes (SRGs) in PD and investigating their molecular underpinnings, as well as their potential diagnostic and therapeutic significance.
methodsBy integrating bioinformatics with experimental validation, the CellAge database provided 278 SRGs for this study. A total of 2925 differentially expressed genes (DEGs) and 31 differentially expressed SRGs (DESRGs) were identified, which are mainly involved in signaling pathways, including nuclear factor kappa light chain enhancer of activated B cells (NF-κB) and interleukin 17 (IL-17). Through protein-protein interaction (PPI) network analysis, 10 hub genes were identified, such as IRF7, IFNG, and BCL6.
resultsIn PD mouse and MN9D cell models by D-galactose (D-gal) and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), combined treatment (D-gal + MPTP) synergistically reduced tyrosine hydroxylase (TH) expression, promoted α-synuclein (α-syn) aggregation, aggravated cellular senescence, and caused significant upregulation of IRF7, whereas IRF7 small interfering RNA (siRNA) intervention reversed senescence- and PD-related pathological changes. Molecular docking analyses identified candidate small molecules targeting hub genes, including fostamatinib and ropsacitinib. In vitro experiments provided preliminary support that these compounds modulated SYK and TYK2 proteins and alleviated pathological phenotypes in cellular models.
conclusionsOverall, this study demonstrates that D-gal-induced aging-like stress accelerates PD-related pathological progression by activating multiple signaling pathways, including JAK-STAT, AGE-RAGE, and NF-κB, thereby promoting inflammation, oxidative stress, and neuronal dysfunction. Key genes including IRF7 may serve as candidate biomarkers, providing preliminary evidence for the role of senescence-like stress in PD pathogenesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.